FDA tuaj yeem pom zoo rau hauv khw muag khoom naloxone nasal spray, autoinjectors

Naloxone, ntim nrog cov lus qhia, yog ib qho ntawm cov khoom muab los ntawm Baltimore Harm Reduction Coalition cov neeg ua haujlwm nthuav tawm.

Amy Davis | Baltimore Sun | Cov duab Getty

Lub Chaw Tswj Xyuas Khoom Noj thiab Tshuaj rau hnub Tuesday tau hais tias nws yuav pom zoo rau cov tshuaj tua kab mob hauv khw muag tshuaj thiab cov tshuaj autoinjectors uas tiv thaiv kev noj tshuaj ntau dhau ntawm opioid, ib feem ntawm nws txoj kev siv zog los nthuav kev nkag mus rau cov tshuaj cawm neeg txoj sia hu ua naloxone.

FDA, hauv kev ntsuam xyuas ua ntej, hais tias cov tshuaj tsuag qhov ntswg uas muaj txog li 4mg ntawm naloxone thiab autoinjectors uas tswj hwm txog li 2 mg ntawm cov tshuaj yuav muaj kev nyab xeeb thiab siv tau zoo rau tib neeg los tswj tus kheej yam tsis muaj tshuaj.

"Peb ntseeg tias qhov yuav tsum tau muab tshuaj rau cov khoom no naloxone tej zaum yuav tsis tsim nyog rau kev tiv thaiv kev noj qab haus huv rau pej xeem," lub koom haum tau hais hauv tsab ntawv ceeb toom ntawm tsoomfwv tau tshaj tawm hnub Tuesday, tab sis tau hais tias nws xav tau cov ntaub ntawv ntxiv los ua kom tiav qhov tseeb.

Opioid overdose tuag tau nce 65% thaum lub sijhawm Covid-19 kis thoob qhov txhia chaw los ntawm 47,000 xyoo 2019 txog ze li 78,000 xyoo 2021, raws li cov ntaub ntawv los ntawm Lub Chaw Tiv Thaiv thiab Tiv Thaiv Kab Mob. Ntau tshaj 564,000 tus neeg tau tuag los ntawm opioids hauv Teb Chaws Asmeskas txij li xyoo 1999 hauv peb lub nthwv dej - thawj zaug los ntawm cov tshuaj opioids, tom qab ntawd los ntawm tus heroin thiab tsis ntev los no los ntawm fentanyl.

CNBC Huv & Science

Nyeem CNBC qhov kev pov hwm kev noj qab haus huv thoob ntiaj teb tshiab:

Thawj Tswj Hwm Trump tau tshaj tawm tias qhov teebmeem opioid yog qhov xwm txheej kev noj qab haus huv rau pej xeem hauv 2017. Lub Tsev Haujlwm Saib Xyuas Kev Noj Qab Haus Huv thiab Tib Neeg tau rov hais dua cov lus tshaj tawm txhua 90 hnub txij thaum ntawd los. Thawj Tswj Hwm Biden tau txuas ntxiv qhov xwm txheej ceev dua thaum lub Cuaj Hli.

FDA Tus Thawj Coj Robert Califf, hauv tsab ntawv tshaj tawm hnub Tuesday, tau hais tias tus tswj hwm tab tom nrhiav txoj hauv kev los tiv thaiv kev tuag opioid los ntawm kev nthuav dav nkag mus rau naloxone. FDA tau txhawb kom cov tuam txhab xa cov ntawv thov rau kev siv cov tshuaj naloxone uas tsis yog tshuaj.

Naloxone yog cov tshuaj uas thim rov qab cov tshuaj ntau dhau los ntawm kev khi rau opioid receptors. Nws tuaj yeem rov ua pa sai sai hauv ib tus neeg uas ua pa maj mam lossis tsis ua txhua yam vim yog kev siv tshuaj ntau dhau ntawm opioid, raws li National Institute of Drug Abuse.

FDA thawj zaug pom zoo ib zaug siv autoinjector uas muaj naloxone nyob rau hauv 2014 hu ua Evzio, thiab ib koob tshuaj nasal tshuaj hu ua NARCAN nyob rau hauv 2015. Lawv ob leeg yuav tsum tau muab tshuaj.

Tau qhov twg los: https://www.cnbc.com/2022/11/15/opioid-crisis-fda-may-approve-over-the-counter-naloxone-nasal-spray-autoinjectors.html